08:00 , Jan 22, 2002 |  BC Week In Review  |  Clinical News

Extended release tramadol: CLC's Cipher Pharmaceuticals Inc. subsidiary submitted an IND to begin U.S. and Canadian Phase II testing of its once-daily tramadol

Canadian Medical Laboratories Ltd. (TSE:CLC), Mississauga, Ontario   Product: Extended release tramadol   Business: Neurological   Therapeutic category: Analgesic, Neurotransmission   Target: Opioid receptors, noradrenaline and serotonin   Description: Once-daily formulation of Johnson & Johnson...
07:00 , Oct 22, 2001 |  BC Week In Review  |  Clinical News

Budesonide Dry Powder Inhaler: Began Phase III study

Canadian Medical Laboratories Ltd. (TSE:CLC), Mississauga, Ontario   Product: Budesonide Dry Powder Inhaler   Business: Autoimmune/Inflammation   Therapeutic category: Steroid   Target: Immune cells   Description: Inhaled dry powder formulation of corticosteroid   Indication: Treat...
07:00 , Sep 25, 2001 |  BC Extra  |  Company News

Cipher, AstraZeneca in asthma deal

Cipher Pharmaceuticals, a subsidiary of Canadian Medical Laboratories (TSE:CLC), received exclusive rights in the Americas from Galephar (San Juan, Puerto Rico) for a budesonide dry powder monodose Inhaler to treat asthma. Cipher plans to begin...
08:00 , Jan 29, 2001 |  BC Week In Review  |  Company News

Canadian Medical Laboratories, Galephar P.R. Inc. deal

CLC subsidiary Cipher Pharmaceuticals licensed from Galephar a formulation of Isotretinoin to treat acne. Cipher said the formulation has increased bioavailability compared to a marketed formulation. Cipher has exclusive rights to the product in the...